Rational combinations of mTOR inhibitors as anticancer strategies

Jesus Garcia-Donas, Juan Francisco Rodriguez-Moreno, Nuria Romero-Laorden, Manuel Hidalgo

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

Mammalian target of rapamycin (mTOR) inhibitors have shown to be active in different malignancies and have reached daily practice. However results are still modest with stabilizations as the most frequent response and ultimately disease progression in all cases. Several feedback loops have been described that could affect the efficacy of these drugs. First, mTOR complex 2 (mTORC2) is known to be resistant to the inhibition by rapamycin analogs leading to a direct activation of Akt. Second, repression of Akt activity by different PI3K/Akt/mTOR inhibitors releases the activity of transcriptional factors that promote the expression of several receptor tyrosine kinases (RTKs). These RTKs will finally stimulate the PI3K/Akt/mTOR pathway and the mitogen-activated protein kinase (MAPK) pathway. Third, any significant decrease in pS6 levels, the final step of the PI3K/Akt/mTOR pathway, may depress the insulin receptor substrate 1 (IRS-1) leading to MAPK activation through PI3K. In order to overcome such resistance, rapalogs have been combined with different compounds that block some of these escape routes. Additionally new drugs able to inhibit simultaneously different steps of the PI3k/Akt/mTOR pathway have been developed.

Original languageEnglish (US)
Title of host publicationmTOR Inhibition for Cancer Therapy: Past, Present and Future
PublisherSpringer-Verlag France
Pages191-216
Number of pages26
ISBN (Print)9782817804927, 9782817804910
DOIs
StatePublished - Jan 1 2015

Fingerprint

Sirolimus
Phosphatidylinositol 3-Kinases
Receptor Protein-Tyrosine Kinases
Mitogen-Activated Protein Kinases
Chemical activation
Insulin Receptor Substrate Proteins
Pharmaceutical Preparations
Disease Progression
Stabilization
Feedback
Neoplasms

ASJC Scopus subject areas

  • Medicine(all)
  • Biochemistry, Genetics and Molecular Biology(all)

Cite this

Garcia-Donas, J., Rodriguez-Moreno, J. F., Romero-Laorden, N., & Hidalgo, M. (2015). Rational combinations of mTOR inhibitors as anticancer strategies. In mTOR Inhibition for Cancer Therapy: Past, Present and Future (pp. 191-216). Springer-Verlag France. https://doi.org/10.1007/978-2-8178-0492-7_9

Rational combinations of mTOR inhibitors as anticancer strategies. / Garcia-Donas, Jesus; Rodriguez-Moreno, Juan Francisco; Romero-Laorden, Nuria; Hidalgo, Manuel.

mTOR Inhibition for Cancer Therapy: Past, Present and Future. Springer-Verlag France, 2015. p. 191-216.

Research output: Chapter in Book/Report/Conference proceedingChapter

Garcia-Donas, J, Rodriguez-Moreno, JF, Romero-Laorden, N & Hidalgo, M 2015, Rational combinations of mTOR inhibitors as anticancer strategies. in mTOR Inhibition for Cancer Therapy: Past, Present and Future. Springer-Verlag France, pp. 191-216. https://doi.org/10.1007/978-2-8178-0492-7_9
Garcia-Donas J, Rodriguez-Moreno JF, Romero-Laorden N, Hidalgo M. Rational combinations of mTOR inhibitors as anticancer strategies. In mTOR Inhibition for Cancer Therapy: Past, Present and Future. Springer-Verlag France. 2015. p. 191-216 https://doi.org/10.1007/978-2-8178-0492-7_9
Garcia-Donas, Jesus ; Rodriguez-Moreno, Juan Francisco ; Romero-Laorden, Nuria ; Hidalgo, Manuel. / Rational combinations of mTOR inhibitors as anticancer strategies. mTOR Inhibition for Cancer Therapy: Past, Present and Future. Springer-Verlag France, 2015. pp. 191-216
@inbook{eed39ad3af3346139004a3eec854b8cc,
title = "Rational combinations of mTOR inhibitors as anticancer strategies",
abstract = "Mammalian target of rapamycin (mTOR) inhibitors have shown to be active in different malignancies and have reached daily practice. However results are still modest with stabilizations as the most frequent response and ultimately disease progression in all cases. Several feedback loops have been described that could affect the efficacy of these drugs. First, mTOR complex 2 (mTORC2) is known to be resistant to the inhibition by rapamycin analogs leading to a direct activation of Akt. Second, repression of Akt activity by different PI3K/Akt/mTOR inhibitors releases the activity of transcriptional factors that promote the expression of several receptor tyrosine kinases (RTKs). These RTKs will finally stimulate the PI3K/Akt/mTOR pathway and the mitogen-activated protein kinase (MAPK) pathway. Third, any significant decrease in pS6 levels, the final step of the PI3K/Akt/mTOR pathway, may depress the insulin receptor substrate 1 (IRS-1) leading to MAPK activation through PI3K. In order to overcome such resistance, rapalogs have been combined with different compounds that block some of these escape routes. Additionally new drugs able to inhibit simultaneously different steps of the PI3k/Akt/mTOR pathway have been developed.",
author = "Jesus Garcia-Donas and Rodriguez-Moreno, {Juan Francisco} and Nuria Romero-Laorden and Manuel Hidalgo",
year = "2015",
month = "1",
day = "1",
doi = "10.1007/978-2-8178-0492-7_9",
language = "English (US)",
isbn = "9782817804927",
pages = "191--216",
booktitle = "mTOR Inhibition for Cancer Therapy: Past, Present and Future",
publisher = "Springer-Verlag France",

}

TY - CHAP

T1 - Rational combinations of mTOR inhibitors as anticancer strategies

AU - Garcia-Donas, Jesus

AU - Rodriguez-Moreno, Juan Francisco

AU - Romero-Laorden, Nuria

AU - Hidalgo, Manuel

PY - 2015/1/1

Y1 - 2015/1/1

N2 - Mammalian target of rapamycin (mTOR) inhibitors have shown to be active in different malignancies and have reached daily practice. However results are still modest with stabilizations as the most frequent response and ultimately disease progression in all cases. Several feedback loops have been described that could affect the efficacy of these drugs. First, mTOR complex 2 (mTORC2) is known to be resistant to the inhibition by rapamycin analogs leading to a direct activation of Akt. Second, repression of Akt activity by different PI3K/Akt/mTOR inhibitors releases the activity of transcriptional factors that promote the expression of several receptor tyrosine kinases (RTKs). These RTKs will finally stimulate the PI3K/Akt/mTOR pathway and the mitogen-activated protein kinase (MAPK) pathway. Third, any significant decrease in pS6 levels, the final step of the PI3K/Akt/mTOR pathway, may depress the insulin receptor substrate 1 (IRS-1) leading to MAPK activation through PI3K. In order to overcome such resistance, rapalogs have been combined with different compounds that block some of these escape routes. Additionally new drugs able to inhibit simultaneously different steps of the PI3k/Akt/mTOR pathway have been developed.

AB - Mammalian target of rapamycin (mTOR) inhibitors have shown to be active in different malignancies and have reached daily practice. However results are still modest with stabilizations as the most frequent response and ultimately disease progression in all cases. Several feedback loops have been described that could affect the efficacy of these drugs. First, mTOR complex 2 (mTORC2) is known to be resistant to the inhibition by rapamycin analogs leading to a direct activation of Akt. Second, repression of Akt activity by different PI3K/Akt/mTOR inhibitors releases the activity of transcriptional factors that promote the expression of several receptor tyrosine kinases (RTKs). These RTKs will finally stimulate the PI3K/Akt/mTOR pathway and the mitogen-activated protein kinase (MAPK) pathway. Third, any significant decrease in pS6 levels, the final step of the PI3K/Akt/mTOR pathway, may depress the insulin receptor substrate 1 (IRS-1) leading to MAPK activation through PI3K. In order to overcome such resistance, rapalogs have been combined with different compounds that block some of these escape routes. Additionally new drugs able to inhibit simultaneously different steps of the PI3k/Akt/mTOR pathway have been developed.

UR - http://www.scopus.com/inward/record.url?scp=84957354396&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84957354396&partnerID=8YFLogxK

U2 - 10.1007/978-2-8178-0492-7_9

DO - 10.1007/978-2-8178-0492-7_9

M3 - Chapter

AN - SCOPUS:84957354396

SN - 9782817804927

SN - 9782817804910

SP - 191

EP - 216

BT - mTOR Inhibition for Cancer Therapy: Past, Present and Future

PB - Springer-Verlag France

ER -